Searched for
CIPLA DIABETES MEDICATION
These large-, mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the old saying goes: Nothing can be ruled out on the street. Which means that one should be prepared for anything. Now, what is the prob...- These large- mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...
- Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...
- Alkem Labs CEO Vikas Gupta may exit companyAlkem Labs, a leading Indian drug maker, is set for a top management change. Vikas Gupta, the CEO for nearly three years, is expected to de...
- Cipla launches drug for obesity, diabetesCipla has launched Yurpeak, a new injectable medication for obesity and type-2 diabetes. This one-weekly therapy, tirzepatide, is now avail...
- Eli Lilly wants to be part of making a big dent in obesity and diabetes, says co's India head Winselow TuckerEli Lilly India chief Winselow Tucker said the company’s strategy of combining a strong product with ecosystem partnerships and patient edu...
- Weight-loss drug Ozempic to debut in India soonNovo Nordisk will launch Ozempic in India. This injectable drug manages type 2 diabetes and aids weight loss. It enters a competitive marke...
- Obesity lab: India becomes ground zero for weight-loss drug raceIndia is emerging as a key player in the global weight management industry, driven by a rising obesity crisis and the impending patent expi...
- Domestic drug companies in a sweet spot as global players look beyond insulinIndian drug cos are increasing their presence in the insulin market. They are competing with multinational corporations. Affordable insulin...
- Sun Pharma aims to launch anti-obesity and type 2 diabetes drug Utreglutide in five years: Dilip ShanghviSun Pharmaceutical, India's largest drugmaker by revenue, plans to launch its experimental anti-obesity and type 2 diabetes drug Utreglutid...
- Cipla shares in focus after receiving CDSCO nod to launch inhalation insulinCipla has secured exclusive rights to distribute and market Afrezza, an inhalable insulin, in India. Developed by MannKind, Afrezza offers ...
- Cipla gets CDSCO nod to launch inhalation insulinCipla received approval from CDSCO to distribute and market Afrezza, an inhalable insulin, in India. Developed by MannKind, Afrezza offers ...
- India to make drugs for diabetes, obesity under PLI by 2026, says reportIndia plans to incentivize local manufacturing of GLP-1 drugs, crucial for treating diabetes and obesity, starting in 2026, as per a govern...
- Cipla vows to crack diabetes segment with licensed branded portfolio"Cipla historically has always been a big respiratory and acute player but not that big in the diabetes area," said Umang Vohra, managing d...
- Eli Lilly lays off 120 employees in India after Cipla saleThe sales team was informed of the decision at a virtual town hall organised last week in conjunction with the media announcement of the de...
- Sales reps testing patients at 'free health camps' in IndiaFree 'health camps' for poor people in India have grown popular, Frederik Joelving, a journalist based in Denmark wrote in the journal.
- Stempeutics plans stem cell device launch in India by mid 2016The company is looking for a strategic partner to globalise and market this device in India and outside.
- Drug sales in rural areas grow at more than 17%, against 11-12% in urban marketsThe companies are now focusing on rural markets, as recent price cuts on drugs for lifestyle diseases have made them more affordable to cos...
- Medicines may cost up to 93% less in govt’s special storesThe government’s initiative to set up a retail network of special drug stores to sell unbranded generic medicines, may bring down cost of s...
- Cos slash prices of popular medicinesPopular medications to treat chest pain, anxiety, allergy and diabetes have become cheaper by between 2% and 39%.
Load More
